ACCRU Clinical Trials - Trial Spotlight

Clinical Trials

Trial Spotlight

Trial Spotlight

ACCRU conducts industry-sponsored and investigator-initiated cancer treatment and symptom management trials across many types of cancer. This feature highlights one of ACCRU’s recent or current innovative trials.

Mantle Cell Lymphoma Study for R/R MCL Patients

ACCRU Trial Spotlight

In ACCRU Study LY-1806, principal investigator Dr. Catherine Diefenbach and her team seek to discover whether a new therapy is safe and effective for patients with relapsed mantle cell lymphoma. It has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy. For more information on the study, go here:

Mantle Cell Lymphoma Study for Transplant-Eligible Patients

ACCRU Trial Spotlight

In ACCRU Study LY1804, principal investigator Dr. Stephen Smith and his team seek to discover whether a high complete response rate can be achieved, including negativity for minimal residual disease. This is a Phase 2 optimization protocol that uses novel agents while reducing chemotheraphy dosing. For more information on the study go here: